[Federal Register Volume 80, Number 56 (Tuesday, March 24, 2015)]
[Notices]
[Pages 15621-15622]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-06648]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Times and Dates:
12:30 p.m.-5:00 p.m., April 15, 2014
8:30 a.m.-12:00 p.m., April 16, 2014
Place: CDC, 1600 Clifton Road NE., Tom Harkin Global Communications
Center, Building 19, Auditorium B, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people. This meeting
will also be Webcast, please see information below.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services (HHS); the Assistant Secretary for Health; the Director,
Centers for Disease Control and Prevention; the Commissioner, Food and
Drug Administration (FDA); and the Administrator, Centers for Medicare
and Medicaid Services (CMS). The advice and guidance pertain to
[[Page 15622]]
general issues related to improvement in clinical laboratory quality
and laboratory medicine practice and specific questions related to
possible revision of the Clinical Laboratory Improvement Amendment
(CLIA) standards. Examples include providing guidance on studies
designed to improve safety, effectiveness, efficiency, timeliness,
equity, and patient-centeredness of laboratory services; revisions to
the standards under which clinical laboratories are regulated; the
impact of proposed revisions to the standards on medical and laboratory
practice; and the modification of the standards and provision of non-
regulatory guidelines to accommodate technological advances, such as
new test methods and the electronic transmission of laboratory
information.
Matters For Discussion: The agenda will include agency updates from
CDC, CMS, and FDA. Presentations and discussions will focus on
laboratory information exchange in health information technology; and
laboratory safety and quality: lessons learned through the Ebola
response.
Agenda items are subject to change as priorities dictate.
Webcast: The meeting will also be Webcast. Persons interested in
viewing the Webcast can access information at: http://wwwn.cdc.gov/cliac/default.aspx
Online Registration Required: All people attending the CLIAC
meeting in-person are required to register for the meeting online at
least 5 business days in advance for U.S. citizens and at least 10
business days in advance for international registrants. Register at:
http://wwwn.cdc.gov/cliac/Meetings/MeetingDetails.aspx#
Register by scrolling down and clicking the ``Register for this
Meeting'' button and completing all forms according to the instructions
given. Please complete all the required fields before submitting your
registration and submit no later than April 8, 2015 for U.S.
registrants and April 1, 2015 for international registrants.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible.
Oral Comments: In general, each individual or group requesting to
make oral comments will be limited to a total time of five minutes
(unless otherwise indicated). Speakers must also submit their comments
in writing for inclusion in the meeting's Summary Report. To assure
adequate time is scheduled for public comments, speakers should notify
the contact person below at least one week prior to the meeting date.
Written Comments: For individuals or groups unable to attend the
meeting, CLIAC accepts written comments until the date of the meeting
(unless otherwise stated). However, it is requested that comments be
submitted at least one week prior to the meeting date so that the
comments may be made available to the Committee for their consideration
and public distribution. Written comments, one hard copy with original
signature, should be provided to the contact person below, and will be
included in the meeting's Summary Report.
Availability of Meeting Materials: To support the green initiatives
of the federal government, the CLIAC meeting materials will be made
available to the Committee and the public in electronic format (PDF) on
the internet instead of by printed copy. Check the CLIAC Web site on
the day of the meeting for materials. Note: If using a mobile device to
access the materials, please verify that the device's browser is able
to download the files from the CDC's Web site before the meeting.
http://wwwn.cdc.gov/cliac/cliac_meeting_all_documents.aspx
Alternatively, the files can be downloaded to a computer and then
emailed to the portable device. An internet connection, power source
and limited hard copies may be available at the meeting location, but
cannot be guaranteed.
Contact Person For Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Programs,
Standards, and Services, Center for Surveillance, Epidemiology and
Laboratory Services, Office of Public Health Scientific Services, CDC,
1600 Clifton Road NE., Mailstop F-11, Atlanta, Georgia 30329-4018;
telephone (404) 498-2741; or via email at [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for CDC and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2015-06648 Filed 3-23-15; 8:45 am]
BILLING CODE 4163-18-P